Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073

Vaccine

Volumn 26, Issue 31, 2008, Pages 3818-3826

  Fytili, P ^a   Dalekos, G N ^b   Schlaphoff, V ^a   Suneetha, P V ^a   Sarrazin, C ^d   Zauner, W ^c   Zachou, K ^b   Berg, T ^e   Manns, M P ^a   Klade, C S ^c   Cornberg, M ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Academic Liver Unit   (Greece)

^c INTERCELL AG   (Austria)

^d SAARLAND UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD8+ T cell; Cross genotype recognition; Epitope variants; Hepatitis C; NS3 1073; Peptide vaccine

Indexed keywords

ALANINE; EPITOPE; HLA A2 ANTIGEN; NONSTRUCTURAL PROTEIN 3; NS3 1073; PEPTIDE VACCINE;

ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC VARIABILITY; GENOTYPE; GERMANY; GREECE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; VIRUS GENOME;

CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; GERMANY; GREECE; HEPACIVIRUS; HEPATITIS C; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROTEIN BINDING; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 46349100543     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.045     Document Type: Article

References (38)

1. Bartenschlager R., and Lohmann V. Replication of hepatitis C virus. J Gen Virol 81 Pt 7 (2000) 1631-1648
2. Pawlotsky J.M. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7 1 (2003) 45-66
3. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 3 (2005) 215-229
4. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
5. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 9 (2000) 1499-1512
6. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197 12 (2003) 1645-1655
7. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 10 (2001) 1395-1406
8. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 6 (2002) 3447-3458
9. Boettler T., Spangenberg H.C., Neumann-Haefelin C., Panther E., Urbani S., Ferrari C., et al. T cells with a CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 12 (2005) 7860-7867
10. Spangenberg H.C., Viazov S., Kersting N., Neumann-Haefelin C., McKinney D., Roggendorf M., et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 42 4 (2005) 828-837
11. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
12. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 5 (2000) 578-582
13. Ward S., Lauer G., Isba R., Walker B., and Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 128 2 (2002) 195-203
14. Lauer G.M., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 79 20 (2005) 12979-12988
15. Gruner N.H., Gerlach T.J., Jung M.C., Diepolder H.M., Schirren C.A., Schraut W.W., et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 181 5 (2000) 1528-1536
16. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 1 (2001) 267-276
17. Firbas C., Jilma B., Tauber E., Buerger V., Jelovcan S., Lingnau K., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24 20 (2006) 4343-4353
18. Manns M.P., Berg T., Wedemeyer H., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients. Hepatology 40 4 (2004) 251A
19. Schlaphoff V., Klade C.S., Jilma B., Jelovcan S.B., Cornberg M., Tauber E., et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 25 37-38 (2007) 6793-6806
20. Wedemeyer H., Mizukoshi E., Davis A.R., Bennink J.R., and Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 75 23 (2001) 11392-11400
21. Urbani S., Amadei B., Fisicaro P., Pilli M., Missale G., Bertoletti A., et al. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 201 5 (2005) 675-680
22. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100 9 (1997) 2376-2385
23. Soderholm J., Ahlen G., Kaul A., Frelin L., Alheim M., Barnfield C., et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55 2 (2006) 266-274
24. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 4 (2006) 1086-1097
25. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87 24 (1990) 9524-9528
26. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152 1 (1994) 163-175
27. Major M.E., Mihalik K., Puig M., Rehermann B., Nascimbeni M., Rice C.M., et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76 13 (2002) 6586-6595
28. Prince A.M., Brotman B., Lee D.H., Pfahler W., Tricoche N., Andrus L., et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 192 10 (2005) 1701-1709
29. Gaudieri S., Rauch A., Park L.P., Freitas E., Herrmann S., Jeffrey G., et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 80 22 (2006) 11094-11104
30. Neumann-Haefelin C., McKiernan S., Ward S., Viazov S., Spangenberg H.C., Killinger T., et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43 3 (2006) 563-572
31. Timm J., Li B., Daniels M.G., Bhattacharya T., Reyor L.L., Allgaier R., et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 46 2 (2007) 339-349
32. Chen J.L., Stewart-Jones G., Bossi G., Lissin N.M., Wooldridge L., Choi E.M., et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 201 8 (2005) 1243-1255
33. Cox A.L., Mosbruger T., Mao Q., Liu Z., Wang X.H., Yang H.C., et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201 11 (2005) 1741-1752
34. Welsh R.M., Kim S.K., Cornberg M., Clute S.C., Selin L.K., and Naumov Y.N. The privacy of T cell memory to viruses. Curr Top Microbiol Immunol 311 (2006) 117-153
35. Cornberg M., Chen A.T., Wilkinson L.A., Brehm M.A., Kim S.K., Calcagno C., et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 116 5 (2006) 1443-1456
36. Kasprowicz V., Ward S.M., Turner A., Grammatikos A., Nolan B.E., Lewis-Ximenez L., et al. Defining the directionality and quality of influenza virus-specific CD8 T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest 118 3 (2008) 1143-1153
37. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76 12 (2002) 6104-6113
38. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127 3 (2004) 924-936